65,437 trials
Epilepsy
Primary: Percentage of Participants Who Achieved Reduction in Daily VPA Dose — 60.6 Percentage of participants
Hepatitis B · Liver Transplantation
Primary: HBV Recurrence — 0; 0 participants
Non-Squamous Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 12.846 Months
Lymphoma
Primary: Overall Objective Response — 45; 31; 6; 1 participants
Obesity · Binge Eating
Primary: Number of Subjects Who Reached Binge Eating Remission — 16; 65 participants
Lung Cancer
Primary: The Objective Overall Response — 7; 12; 7; 19 participants
Hodgkin's Disease · Leukemia · Myelodysplastic Syndrome
Primary: Safety of Rituximab Prophylaxis — 23 participants
Shoulder Pain
Primary: Number of Participants That Need an Airway Intervention. — 0; 5 participants
Parkinson's Disease
Primary: Severity of PD (Unified Parkinson Disease Rating Scale - UPDRS, 2008 Version) — 24.7; 30.5; 24.4; 30.2 units on a scale
Leukemia · Myeloproliferative Disorders · Myelodysplastic-Myeloproliferative Diseases
Primary: Two-year Overall Survival — 46; 51 percentage of patients
Obesity
Primary: Weight Loss — -8.1; -6.9 kg
Hepatic Insufficiency
Primary: AUC (0-inf) of Nintedanib — 200; 674; 92.7; 77.8 ng*h/mL
Smoking · Nicotine Dependence · Mental Disorders
Primary: Acceptance of Wisconsin Tobacco Quit Line Services — 11; 6; 6 participants
Melanoma · Skin Cancer · Cancer
Primary: Overall Objective Response (Complete Response or Partial Response) — 2; 2; 15 participants
HIV Infections
Primary: Number of Participants With Suspected Adverse Drug Reaction Leading to Treatment Termination — 0 participants